Showing results (11-20 of 39) with videos related to
Sort By:
Pageof 4
Thoracic Cancer|October 4, 2023
Development and validation of a nomogram based on preoperative variables for predicting recurrence-free survival in stage IA lung adenocarcinomaJiaxi Xu, Hui Zeng, Guochao Zhang, et al.Frontiers in Oncology|October 3, 2022
Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trialsWenjie Xu, Yuxiang Zheng, Zizheng Suo, et al.Thoracic Cancer|May 24, 2023
Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironmentChao Wang, Kailun Fei, Lihui Liu, et al.Frontiers of Medicine|February 27, 2023
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directionsJia Zhong, Hua Bai, Zhijie Wang, et al.Journal for Immunotherapy of Cancer|October 29, 2020
Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinomaXiran He, Yang Du, Zhijie Wang, et al.Frontiers in Oncology|April 17, 2023
Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center studyKailun Fei, Gang Guo, Jie Wang, et al.BMC Medicine|November 10, 2022
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumorsPei Zhang, Yang Du, Hua Bai, et al.Cancer Immunology Research|November 14, 2019
TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung CancerJiefei Han, Jianchun Duan, Hua Bai, et al.Iscience|May 11, 2023
A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinomaJiachen Xu, Zhenlin Yang, Wenchuan Xie, et al.JAMA Network Open|October 5, 2020
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 TrialZhijie Wang, Jianming Ying, Jiachen Xu, et al.Pageof 4